Differential profile gene expression and its influence on survival in patients with uterine body cancer by integrative bioinformation and clinical genetic analysis

Purpose of the study. To analyze the data on differential gene expression with the isolation of the main signaling pathways in endometrial carcinoma and rare forms of uterine cancer using bioinformation technologies and to determine the effect of the genetic profile on the survival of patients.

Materials and methods. The identification of differentially expressed genes in tumor cells in endometrial carcinoma, as well as their effect on survival, was carried out using the Gene Expression Omnibus database, the Atlas of the cancer genome, DAVID, STRING and the Bioconductor packages, Cytoscape network software. In addition, we analyzed the survival rate of 2756 patients with uterine cancer according to the cancer registry of Rostov and Volgograd regions. Real-time PCR analysis was used to assess the expression of the gene CDKN2A in tumor cells in endometrial carcinoma, clear cell and serous carcinoma of the uterine body, followed by an assessment of the effect of gene expression on patient survival.

Results. In uterine cancer, high expression activity of the genes CDKN2A, L1CAM, ERBB2, PAX8, UBE2C, CLDN4, KIF2C, AURKB, and TNNT1 was found in comparison with normal endometrium. Expression of the gene CDKN 2A sharply increased in serous and clear cell carcinomas and was many times higher than in endometrioid tumors. Overexpression of the gene CDKN2A in serous and clear cell carcinomas is associated with the development of death and lost its independence as a predictor of endometrial adenocarcinoma.

Conclusion. Evaluation of gene expression CDKN 2A is promising for expanding the molecular genetic classification of uterine cancer and predicting the survival of patients with rare forms of uterine cancer.

1. Gryaznov S.A. Perspectives of bioinformatics. International Journal of the Humanities and Natural Sciences. 2021; 6–2(57): 100–102. https://doi.org/10.24412/2500–1000–2021–6–2–100–102

2. Pereginya O.V., Lutsenko T.M. Тranslation medicine, biomedicine and medical biotechnology: the transition to personalized medicine. Biotechnologia Acta. 2020; 13 (2): 5–11. https://doi.org/10.15407/biotech13.02.005

3. Dedov I.I. Personalized medicine. Bulletin of the Russian Academy of Medical Sciences. 2019; 74 (1): 61–70. https://doi.org/10.15690/vramn1108

4. Osipova T. V., Bukhman V. M. Biomarkers of translational medicine. Russian Biotherapeutic Journal. 2018; 17 (1): 6–13. https://doi.org/10.17650/1726–9784–2018–17–1–6–13

5. Huttlin E. L., Bruckner R. J., Paulo J.A. Cannon J.R., Ting L., Baltier K., Colby G. Architecture of the human interactome defines protein communities and disease networks. Nature. 2017; 545 (7655): 505–509. https://doi.org/10.1038/nature22366

6. Glukhov A.I., Khuchua Z.A., Gryzunova G.K., Astakhov D.V., Danilevsky M.I. Interactomics in translational medicine. Sechenovskiy Bulletin. 2018; 1 (31): 4–15.

7. Sprindzhuk M.V., Titov L.P., Konchits A.P., Mozharovskaya L.V. Modern algorithms for processing transcriptome data: a review of methods and results of approbation. System Analysis and Applied Informatics. 2021; 2: 54–62.

8. Kit O.I., Gvaldin D. Yu., Trifanov V. S., Kolesnikov E.N., Timoshkina N.N. Molecular and genetic features of pancreatic neuroendocrine tumors. Genetics. 2020; 56 (2): 142–160. https://doi.org/10.31857/S001667582002006X

9. Kit O.I., Timoshkova M. Yu., Maksimov A. Yu., Verenikina E.V., Kecheryukova M.M., Lukbanova E.A. Expression of miRNA in patients with malignant and precancerous diseases of the cervix. Medical Bulletin of the North Caucasus. 2020; 15 (4): 519–522. https://doi.org/10.14300/mnnc.2020.15122

10. Ung M.H., Liu C.C., Cheng C. Integrative analysis of cancer genes in a functional interactome. Sci Rep. 2016; 6: 29228. https://doi.org/10.1038/srep29228

11. Talhouk A., McConechy M.K., Leung S. Confirmation of ProMisE: a simple, genomics-based clinical classifier for endometrial cancer. Cancer. 2017; 123: 802–813. https://doi.org/10.1002/cncr.30496

12. Wujcicka W., Zajac A., Szyllo K., Smolarz B., Romanowicz H., Stachowiak G. Association of SNPs in CDKN2A (P14ARF) tumour suppressor gene with endometrial cancer in postmenopausal women. In Vivo. 2020; 34 (2): 943–951. https://doi.org/10.21873/invivo.11862.